Skip to main content
Premium Trial:

Request an Annual Quote

Ubiquitome, DKSH Sign Asia Pacific Distribution Agreement for Mobile COVID-19 Testing Platform

NEW YORK – Ubiquitome said on Monday that it has signed an exclusive agreement with Switzerland-based market expansion services group DiethelmKellerSiberHegner (DKSH) to market and sell Ubiquitome's mobile PCR-based COVID-19 testing platform Liberty16 in several countries in the Asia-Pacific region.

Under the terms of the deal, DKSH's Singapore-based technology business unit will provide marketing, sales, distribution, logistics, and after-sales services for the Liberty16 in Australia, Cambodia, Indonesia, Laos, Malaysia, Myanmar, New Zealand, the Philippines, Singapore, Thailand, and Vietnam. DKSH will also seek regulatory approval for the device in each of these markets, the company said.

Financial terms of the agreement were not disclosed.

The Liberty16 is a real-time PCR device that amplifies specific target DNA sequences to show the presence of any DNA of interest. It can run 16 tests at once, connects via Bluetooth to its own proprietary iPhone App, is battery-operated, and weighs 2.5 kg. Ubiquitome has suggested that the device's mobility makes it ideal to be used in places like airports to pre-screen international travelers for COVID-19.

Earlier this month, Ubiquitome said it had received NZ$528,927 ($324,388) from the government of New Zealand to help increase its manufacturing capacity for the Liberty16 in Auckland. The company said it also plans to apply for Emergency Use Authorization from the US Food and Drug Administration.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more